Future-Proofing Your USP <87> Strategy: Preparing For The Next Generation Of Biological Reactivity Testing

The pending December 1, 2026 update to USP <87> marks a decisive industry shift toward modern, science-based in vitro testing and quantitative risk assessment for pharmaceutical and medical device manufacturing. Navigating these regulatory updates requires a proactive strategy to evaluate material qualification, biological evaluation, and laboratory planning long before mandatory enforcement. Modernizing testing frameworks early prevents operational bottlenecks, minimizes reliance on legacy protocols, and aligns compliance strategies with evolving global standards. Exploring anticipated structural changes, validation impacts, and proactive readiness steps allows organizations to safeguard product development timelines while enhancing testing precision.

Access the full webinar to gain expert insights on structuring a future-proof biological reactivity compliance framework.